April 28 (Reuters) - Merck KGaA's CEO said on Monday that the German group's takeover price for U.S. biotech firm SpringWorks SWTX.O was firmly agreed and "final", when asked about the potential of any rival bidders for the takeover target.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.